ELV · Elevance Health, Inc.
$394.43
-4.68 (-1.17%)
At close · Aug 28
Market Cap
$86.55B
Shares
216.87M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$394.43
Open$400.81
Day$394.40–403.16
52W close$280.74–426.79
Avg vol 30d995K
Short int5.4M · 2.5% float · 5.7d
Short vol64%
Last earningsJul 15, 2026
DataJan 2020–Aug 2026
Filing10-Q · Jul 15
Up next
Next earnings call
Oct 13, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 15, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Bullish
Fundamentals
Strong
Quant / Vol
Moderate
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+10%
above
Price vs 50-day avg
−0%
below
RSI (14)
49
neutral
MACD trend
Positive
52-week position
78%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+5%
trailing
6-month return
+41%
trailing
YTD return
+13%
this year
Relative strength
+27%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $395 › 200d $357 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +266 funds added
Insider flow
Accumulating
Net +$1.2M over 90 days · 50% sells
Short interest
Falling
2.49% of float · ▼ -3.2% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,616 holders — mid 3-yr range
Squeeze score
55
elevated · 0–100
Fundamentals
Revenue growth
+12%
Y/Y
EPS growth
−2%
Y/Y
Free cash flow
$3.2B
Valuation
P/E 17.7
below peers
Buyback
$5.3B
remaining
Balance sheet
$22.6B
net debt
Quant / Vol
risk profile
Volatility
35%
annualized · 1-yr
Max drawdown
−26%
past year
ATR
2.5%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Jun 30, 2026
full year 2026
Adjusted diluted earnings per share
Non-GAAP
at least $27.00
2027
Adjusted EPS growth
Non-GAAP
at least 12%
next year
Adjusted earnings growth
Non-GAAP
at least 12%
this year
Medicare Advantage margin
at least 2%
Prior guidance
period ended
· from the Earnings Call filed Sep 30, 2025
2025 adjusted EPS
· 2025 full year
$30.00
Guided vs delivered
· last 2 settled
GAAP net income per diluted share
2025
guided $24.10
$25.21
Beat +4.6%
EPS
for the year
guided at least $32.85
$25.22
Miss −23.2%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+10%
Bullish
Price vs 50-day avg
−0%
Neutral
RSI (14)
49
Neutral
MACD trend
Positive
Bullish
52-week position
78%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $395 › 200d $357 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +266 funds added
Insider flow
Accumulating
Net +$1.2M over 90 days · 50% sells
Short interest
Falling
2.49% of float · ▼ -3.2% MoM · 5.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
1,616 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $281
Now $394 · 78%
Range high $427
vs 200-day avg +10%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted Operating Gain non-GAAP | 1.8B | Q2 2026 | — |
|
|
|||
| Adjusted Operating Margin non-GAAP | 3.6% | Q2 2026 | — |
|
|
|||
| Benefit expense ratio | 89.7% | Q2 2026 | — |
| Carelon Services Consumers Served | 92.4M | Q2 2026 | — |
|
|
|||
| CarelonRx Quarterly Adjusted Scripts non-GAAP | 80.9M | Q2 2026 | — |
|
|
|||
| Days in Claims Payable | 45.4 | Q2 2026 | — |
| Medical membership | 44.9M | Q2 2026 | — |
| Operating cash flow | 1.9B | Q2 2026 | — |
| Adjusted shareholders' earnings per diluted share non-GAAP | $12.58 | Three Months Ended March 31, 2026 | — |
|
|
|||
| Adjusted shareholders' net income non-GAAP | $2.77B | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Shareholders' net income $1.76B
+$935M Accrual related to CMS notice
+$129M Business optimization program charges
+$112M Amortization of other intangible assets
+$78M Net losses on financial instruments
+$47M Transaction and integration related costs
+$7M Litigation and settlement expenses
-$300M Tax impact of non-GAAP adjustments
= Adjusted shareholders' net income $2.77B
|
|||
| BlueCard® Medical Membership | 6.58M | As of March 31, 2026 | — |
| Commercial Fee-Based Medical Membership | 27.75M | As of March 31, 2026 | — |
| Commercial Risk-Based Medical Membership | 4.86M | As of March 31, 2026 | — |
| Employer Group Fee-Based Medical Membership | 21.17M | As of March 31, 2026 | — |
| Employer Group Risk-Based Medical Membership | 3.44M | As of March 31, 2026 | — |
| Federal Employee Program Medical Membership | 1.56M | As of March 31, 2026 | — |
| Individual Medical Membership | 1.42M | As of March 31, 2026 | — |
| Medicaid Medical Membership | 8.46M | As of March 31, 2026 | — |
| Medicare Advantage Medical Membership | 1.9M | As of March 31, 2026 | — |
| Medicare Supplement Medical Membership | 888K | As of March 31, 2026 | — |
| Reportable segments adjusted operating gain non-GAAP | $3.26B | Three Months Ended March 31, 2026 | — |
|
|
|||
| Total Medical Membership | 45.42M | As of March 31, 2026 | — |
| Total Medicare Medical Membership | 2.79M | As of March 31, 2026 | — |
| Adjusted Effective Tax Rate non-GAAP | 17.6% | Full Year 2025 | — |
| Adjusted operating expense non-GAAP | $20.72B | Twelve Months Ended December 31, 2025 | — |
| Adjusted operating expense ratio non-GAAP | 10.5% | Twelve Months Ended December 31, 2025 | — |
| Commercial Fee-Based | 27.09M | Year-End 2025 | — |
| Commercial Risk-Based | 4.92M | Year-End 2025 | — |
| Current year medical claims paid as a percentage of current year net incurred medical claims | 89.5% | Full Year 2025 | — |
| Diluted Shares | 224.6M | Full Year 2025 | — |
| Federal Employee Program | 1.6M | Year-End 2025 | — |
| Medicaid | 8.5M | Year-End 2025 | — |
| Medicare Advantage | 2.23M | Year-End 2025 | — |
| Medicare Supplement | 882K | Year-End 2025 | — |
| Operating expense ratio | 10.6% | Twelve Months Ended December 31, 2025 | — |
| Prior year redundancies in the current year as a percentage of prior year net incurred medical c | 1% | Full Year 2025 | — |
| Prior year redundancies in the current year as a percentage of prior year net medical claims pay | 9% | Full Year 2025 | — |
| Risk-Based | 18.14M | Year-End 2025 | — |
| Total Medical Enrollment | 45.23M | Year-End 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Healthcare Plans — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ELV
this stock
Elevance Health, Inc.
|
$86.55B | +12.5% | +12.5% | 17.7 | 2.5% |
|
UNH
Unitedhealth Group Inc
|
$352.71B | +19.0% | +11.8% | — | 1.7% |
|
CVS
CVS HEALTH Corp
|
$119.49B | +17.3% | +7.8% | 24.7 | 1.3% |
|
CI
Cigna Group
|
$74.06B | +1.3% | +11.2% | 11.6 | 2.0% |
|
HUM
Humana Inc
|
$47.14B | +50.5% | +10.1% | 41.9 | 2.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ELV | -1.5% | +5.0% | +40.5% | +5.0% | +12.5% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -2.0% | +2.0% | +27.1% | +2.0% | -0.3% |
Capital returns
Latest dividend
$1.72
/ share · ex Jun 10, 2026
Declared · upcoming
$1.72
/ share · ex Sep 10, 2026
Paid (TTM)
$6.86
/ share · 4 payouts
Dividend yield (TTM, derived)
1.74%
Buyback program
· as of Jun 30, 2026
Authorized
—
Spent (derived)
—
Remaining
$5.34B
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1156039
CUSIP
036752103
13F (30d)
1118 filings
1059 filers
Visit website
Investor relations